Da montelukast og dets metabolitter elimineres via galden, er dosisjustering ikke nødvendig hos patienter med nedsat nyrefunktion.
Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment.